Molecular Cancer (Mar 2021)
Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma
- Yan Xu,
- Yuan Li,
- Jiankang Jin,
- Guangchun Han,
- Chengcao Sun,
- Melissa Pool Pizzi,
- Longfei Huo,
- Ailing Scott,
- Ying Wang,
- Lang Ma,
- Jeffrey H. Lee,
- Manoop S. Bhutani,
- Brian Weston,
- Christopher Vellano,
- Liuqing Yang,
- Chunru Lin,
- Youngsoo Kim,
- A. Robert MacLeod,
- Linghua Wang,
- Zhenning Wang,
- Shumei Song,
- Jaffer A. Ajani
Affiliations
- Yan Xu
- Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Yuan Li
- Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Jiankang Jin
- Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Guangchun Han
- Departments of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Chengcao Sun
- Departments of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Melissa Pool Pizzi
- Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Longfei Huo
- Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Ailing Scott
- Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Ying Wang
- Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Lang Ma
- Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Jeffrey H. Lee
- Departments of Gastroenterology&Hepatology, The University of Texas MD Anderson Cancer Center
- Manoop S. Bhutani
- Departments of Gastroenterology&Hepatology, The University of Texas MD Anderson Cancer Center
- Brian Weston
- Departments of Gastroenterology&Hepatology, The University of Texas MD Anderson Cancer Center
- Christopher Vellano
- Center for Co-Clinical Trial, The University of Texas MD Anderson Cancer Center
- Liuqing Yang
- Departments of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Chunru Lin
- Departments of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Youngsoo Kim
- Ionis Pharmaceuticals, Inc.
- A. Robert MacLeod
- Ionis Pharmaceuticals, Inc.
- Linghua Wang
- Departments of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Zhenning Wang
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University
- Shumei Song
- Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Jaffer A. Ajani
- Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1186/s12943-021-01351-5
- Journal volume & issue
-
Vol. 20,
no. 1
pp. 1 – 2
Abstract
An amendment to this paper has been published and can be accessed via the original article.
